Skip to content

MBX Biosciences, Inc. MBX Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Amgen logo
AmgenAMGN
-$716M-60.2%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$54.19M-14.3%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$36.26M+183%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$42.74M-2,579%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$123.83M-585%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s investing cash flow?
MBX Biosciences, Inc. (MBX) reported investing cash flow of -$97.1M in Q1 2026.
How has MBX Biosciences, Inc.'s investing cash flow changed year-over-year?
MBX Biosciences, Inc.'s investing cash flow decreased by 3109.8% year-over-year, from $3.23M to -$97.1M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.